Return to List

Study Summary
No. 2003-0924:.......Kidney......Nizar M. Tannir......Genitourinary Medical Oncology
.
Study Summary Title
Study Summary
Number:		2003-0924
Study Title:A Phase III, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma
.
Physician New Patient Referral
Name:Nizar M. TannirPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Genitourinary Medical OncologyReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-2830
Contact us about clinical trials
.
General Information
Disease Group:KidneySupported By:Wyeth Research
Phase of Study:Phase IIIReturn
Visit:		CLNC VSTS REQUIRED WKLY FOR ALL 3 ARMS OF TRIAL DURING TRTMNT PERIOD. FOR IFN ALFA ALONE PTS (TRTMNT ARM A) REMAINING IN STDY LONGER THAN 16 WKS, DAY 8 & 22 VSTS NOT REQUIRED IF CLNCLY APPROP (I.E. IFN ALFA DOSE STABILIZED).
Treatment
Agents:		Collection
Imaging
Roferon-A
CCI-779		Home Care:IFN ALFA (ROFERON)
Treatment Loc:outpatient
Estimated
Length of Stay
in Houston:		N/A
Description/
Intervention:		Unavailable
.
Study Objectives / Outcomes
Unavailable
.
Study Status Information
Study Activation / Registration Date:09/29/2004
IRB Review and Approval Date:03/03/2004
Study Type:Therapeutic
Recruitment Status:Closed
Projected Accrual:40
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:Age equal to or greater than 18 years.

Signed and dated informed consent form.
.
Links
Registration Number:
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center